Cargando…

Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy

INTRODUCTION: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell lung carcinoma is limited. We aimed to summarize the clinical data of these patients to explore the survival prognostic factors for this population. METHODS: From September 1995 to July 2011, patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Hao, Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Wu, Dan, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948689/ https://www.ncbi.nlm.nih.gov/pubmed/27471395 http://dx.doi.org/10.2147/OTT.S106696

Ejemplares similares

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study
por: Chen, Ya, et al.
Publicado: (2022)

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer
por: Huynh, Linda My, et al.
Publicado: (2022)

Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer
por: Jones, Gregory D., et al.
Publicado: (2021)

Survival and prognostic factors in oligometastatic breast cancer
por: van Ommen-Nijhof, Annemiek, et al.
Publicado: (2022)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer
por: Matoska, Thomas, et al.
Publicado: (2023)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

Risk Prediction Model for Synchronous Oligometastatic Non-Small Cell Lung Cancer: Thoracic Radiotherapy May Not Prolong Survival in High-Risk patients
por: Meng, Chunliu, et al.
Publicado: (2022)

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival
por: De, Brian, et al.
Publicado: (2023)

Local ablative radiotherapy for oligometastatic non-small cell lung cancer
por: Suh, Yang-Gun, et al.
Publicado: (2019)

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer
por: Santos, Patricia Mae G., et al.
Publicado: (2022)

Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas
por: Safi, S. A., et al.
Publicado: (2021)

Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
por: Fleckenstein, Jochen, et al.
Publicado: (2016)

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
por: Wang, Xiao-Shan, et al.
Publicado: (2022)

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
por: Xu, Jianlin, et al.
Publicado: (2016)

Local therapy treatment conditions for oligometastatic non-small cell lung cancer
por: Zhang, Suli, et al.
Publicado: (2022)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer
por: Werner, Raphael S., et al.
Publicado: (2021)

Synchronous Oligometastatic Non-Small Cell Lung Cancer and Isolated Renal Cell Carcinoma: A Case Report and Literature Review
por: Nguyen, Timothy K, et al.
Publicado: (2015)

Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
por: Cortinovis, Diego, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease
por: Mehrens, Dirk, et al.
Publicado: (2021)

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer
por: Ouyang, Wen, et al.
Publicado: (2019)

Lobectomy Can Improve the Survival of Patients With Non-small Cell Lung Cancer With Lung Oligometastatic
por: Wang, Lingwei, et al.
Publicado: (2021)

Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer
por: Billing, David L., et al.
Publicado: (2021)

Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature
por: Boni, Andrea, et al.
Publicado: (2018)

The metabolic repression effect of carbon-ion radiotherapy in synchronous hormone-sensitive oligometastatic prostate cancer
por: Zhang, Zhenshan, et al.
Publicado: (2023)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Classifying Oligometastatic Non-Small Cell Lung Cancer
por: Blumenthaler, Alisa N., et al.
Publicado: (2021)

Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Shi, Yu, et al.
Publicado: (2019)

Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2023)

Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study
por: Shao, Yi, et al.
Publicado: (2020)

Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Successful treatment of a patient with oligometastatic mesothelioma to the brain
por: Li, Selena S., et al.
Publicado: (2020)

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
por: Qiao, Rong, et al.
Publicado: (2019)

Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
por: Hu, Xiaolong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vmvsp2hjok8k55htdkpfglkuun